Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04791514 · ClinicalTrials.gov registry record · Phase 2
A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
A Phase 2 study, sponsored by Insmed Incorporated.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04791514 is a Phase 2 study that was terminated before completion, run by Insmed Incorporated. The registered enrollment target is 1 participants.
The verdict
NCT04791514, a Phase 2 study, was terminated before completion, sponsored by Insmed Incorporated.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of single dose of treprostinil palmitil inhalation powder (TPIP) in participants with pulmonary arterial hypertension (PAH).
Interventions
- DRUG Treprostinil Palmitil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2022-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04791514
The ClinicalTrials.gov registry entry for NCT04791514 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Treprostinil Palmitil is the first listed.
NCT04791514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04791514 about?
NCT04791514 is a clinical study titled "A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)". The main purpose of this study is to evaluate the safety and tolerability of single dose of treprostinil palmitil inhalation powder (TPIP) in participants with pulmonary arterial hypertension (PAH).
What is the current status of trial NCT04791514?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2022-03-29. Estimated completion is 2022-08-26.
What interventions are being tested in trial NCT04791514?
The interventions under investigation include: Treprostinil Palmitil (DRUG).
Who is sponsoring clinical trial NCT04791514?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.